Ponstan Adverse Reactions

Blood and lymphatic system disorders: agranulocytosis, aplastic anemia, autoimmune hemolytic anemia*, bone marrow hypoplasia, decreased hematocrit, eosinophilia, leukopenia, pancytopenia, thrombocytopenic purpura, platelet aggregation inhibition.
Immune system disorders: anaphylaxis.
Metabolism and nutrition disorders: glucose intolerance in diabetic patients, hyponatremia, fluid retention.
Psychiatric disorders: nervousness.
Nervous system disorders: aseptic meningitis, blurred vision, convulsions, dizziness, drowsiness, headache and insomnia.
Eye disorders: eye irritation, reversible loss of color vision.
Ear and labyrinth disorders: ear pain.
Cardiac disorders: palpitation.
Vascular disorders: hypotension, hypertension.
Respiratory, thoracic and mediastinal disorders: asthma, dyspnea.
Gastrointestinal disorders: gastrointestinal inflammation, gastrointestinal hemorrhage, gastrointestinal ulcer, gastrointestinal perforation.
The most frequently reported side effects associated with mefenamic acid involve the gastrointestinal tract. Diarrhea appears to be the most common side effect and is usually dose-related. It generally subsides on dosage reduction, and rapidly disappears on termination of therapy. Some patients may not be able to continue therapy.
The following are the most common gastrointestinal side effects: abdominal pain, diarrhea and nausea with or without vomiting.
Less frequently reported gastrointestinal/hepatobiliary side effects include: anorexia, cholestatic jaundice, colitis, constipation, enterocolitis, flatulence, gastric ulceration with and without hemorrhage, mild hepatic toxicity, hepatitis, hepatorenal syndrome, pyrosis, pancreatitis and steatorrhea.
Skin and subcutaneous tissue disorders: angioedema, edema of the larynx, erythema multiforme, facial edema, Lyell's syndrome (toxic epidermal necrolysis), perspiration, pruritus, rash, Stevens-Johnson syndrome, urticaria and dermatitis exfoliative.
Renal and urinary disorders: dysuria, hematuria, renal failure including papillary necrosis and tubulointerstitial nephritis, glomerulonephritis, nephrotic syndrome.
General disorders and administration site conditions: edema.
Investigations: urobilinogen urine (false-positive), liver function test abnormal.
Paediatric patients: General disorders and administration site conditions: hypothermia.
*Reports are associated with ≥12 months of mefenamic acid therapy and the anemia is reversible with discontinuation of therapy.